Challenges and Unmet Needs in the Treatment of HER2-Positive Breast Cancer

Podcast

In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

Related Videos
Erin Frances Cobain, MD
Erin Frances Cobain, MD
Video 6 - "Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape"
Manmeet Singh Ahluwalia, MD
Rita Nanda, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Related Content
Erin Frances Cobain, MD, of the University of Michigan Rogel Cancer Center

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

May 2nd 2024
Article
Andre H. Goy, MD, vice president, physician in chief, Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma, academic chairman, Oncology, Hackensack Meridian School of Medicine; professor, medicine, Georgetown University

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

May 6th 2024
Podcast
Erin Frances Cobain, MD

The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations

April 30th 2024
Article
Ryan Merkow, MD, MS, associate professor, surgery, director, Surgical Cancer Quality, associate director, Health Services Research, Department of Surgery, director, Hepatic Artery Infusion Pump Program, University of Chicago Medicine Comprehensive Cancer Center and Cancer Service Line; Louise Catherine Connell, MB BCh BAO, BMedSc, assistant attending physician, Memorial Sloan Kettering Cancer Center

Merkow and Connell Highlight Considerations for HAI Pump Use in CRC

May 2nd 2024
Podcast
Mafalda Oliveira, MD, PhD

CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

April 29th 2024
Article
FDA

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

April 29th 2024
Article